Body Mass Index and Prostate-Specific Antigen Failure Following Brachytherapy for Localized Prostate Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 71, Issue 5, 2008, Pages 1302-1308

  Efstathiou, Jason A ^a   Skowronski, Rafi Y ^a   Coen, John J ^a   Grocela, Joseph A ^a   Hirsch, Ariel E ^b   Zietman, Anthony L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON MEDICAL CENTER   (United States)

Author keywords

BMI; Brachytherapy; Obesity; Prostate cancer; PSA failure

Indexed keywords

ANTIGENS; FOOD PROCESSING; REGRESSION ANALYSIS;

ANDROGEN DEPRIVATION THERAPY; BMI; BODY MASS INDEX; BRACHYTHERAPY; COVARIATES; EXTERNAL BEAM RADIATION THERAPY; GLEASON SCORE; LOCALIZED PROSTATE CANCER; OBESITY; PROSTATE CANCER; PROSTATE-SPECIFIC ANTIGEN; PSA FAILURE; RADICAL PROSTATECTOMY;

PEELING;

BICALUTAMIDE; FLUTAMIDE; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; BODY MASS INDEX; BRACHYTHERAPY; COMBINED MODALITY THERAPY; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 47149098453     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.11.073     Document Type: Article

References (60)

1. Ogden C.L., Carroll M.D., Curtin L.R., et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295 (2006) 1549-1555
2. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
3. Rapp K., Schroeder J., Klenk J., et al. Obesity and incidence of cancer: A large cohort study of over 145,000 adults in Austria. Br J Cancer 93 (2005) 1062-1067
4. Calle E.E., Rodriguez C., Walker-Thurmond K., et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348 (2003) 1625-1638
5. Andersson S.O., Wolk A., Bergstrom R., et al. Body size and prostate cancer: A 20-year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst 89 (1997) 385-389
6. Giovannucci E., Rimm E.B., Liu Y., et al. Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst 95 (2003) 1240-1244
7. Presti Jr. J.C., Lee U., Brooks J.D., et al. Lower body mass index is associated with a higher prostate cancer detection rate and less favorable pathological features in a biopsy population. J Urol 171 (2004) 2199-2202
8. Engeland A., Tretli S., and Bjorge T. Height, body mass index, and prostate cancer: A follow-up of 950000 Norwegian men. Br J Cancer 89 (2003) 1237-1242
9. Schuurman A.G., Goldbohm R.A., Dorant E., et al. Anthropometry in relation to prostate cancer risk in the Netherlands Cohort Study. Am J Epidemiol 151 (2000) 541-549
10. Rodriguez C., Patel A.V., Calle E.E., et al. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 10 (2001) 345-353
11. Snowdon D.A., Phillips R.L., and Choi W. Diet, obesity, and risk of fatal prostate cancer. Am J Epidemiol 120 (1984) 244-250
12. Siddiqui S.A., Inman B.A., Sengupta S., et al. Obesity and survival after radical prostatectomy: A 10-year prospective cohort study. Cancer 107 (2006) 521-529
13. Gong Z., Agalliu I., Lin D.W., et al. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer 109 (2007) 1192-1202
14. Kane C.J., Bassett W.W., Sadetsky N., et al. Obesity and prostate cancer clinical risk factors at presentation: Data from CaPSURE. J Urol 173 (2005) 732-736
15. Amling C.L., Riffenburgh R.H., Sun L., et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 22 (2004) 439-445
16. Freedland S.J., Aronson W.J., Kane C.J., et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: A report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol 22 (2004) 446-453
17. Freedland S.J., Grubb K.A., Yiu S.K., et al. Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center. J Urol 174 (2005) 919-922
18. Strom S.S., Wang X., Pettaway C.A., et al. Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res 11 (2005) 6889-6894
19. Strom S.S., Kamat A.M., Gruschkus S.K., et al. Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer. Cancer 107 (2006) 631-639
20. Efstathiou J.A., Chen M.H., Renshaw A.A., et al. Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer. Cancer 109 (2007) 1493-1498
21. 125I brachytherapy. Int J Radiat Oncol Biol Phys 51 (2001) 31-40
22. Kollmeier M.A., Stock R.G., and Stone N. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: Importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys 57 (2003) 645-653
23. Merrick G.S., Butler W.M., Wallner K.E., et al. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer. W V Med J 101 (2005) 168-171
24. Zelefsky M.J., Hollister T., Raben A., et al. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 47 (2000) 1261-1266
25. Zelefsky M.J., Kuban D.A., Levy L.B., et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 67 (2007) 327-333
26. Brachman D.G., Thomas T., Hilbe J., et al. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: Results from a single practice. Int J Radiat Oncol Biol Phys 48 (2000) 111-117
27. Potters L., Morgenstern C., Calugaru E., et al. 12-Year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 173 (2005) 1562-1566
28. Blasko J.C., Mate T., Sylvester J.E., et al. Brachytherapy for carcinoma of the prostate: Techniques, patient selection, and clinical outcomes. Semin Radiat Oncol 12 (2002) 81-94
29. Zelefsky M.J., Moughan J., Owen J., et al. Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 Patterns of Care survey for prostate cancer. Int J Radiat Oncol Biol Phys 59 (2004) 1053-1061
30. Merrick G.S., Butler W.M., Wallner K.E., et al. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy. Urology 65 (2005) 95-100
31. Beahrs O.H., Henson D.E., and Hutter R.V.P. American Joint Committee on Cancer: Manual for staging cancer. 4th ed. (1992), Lippincott, Philadelphia, PA
32. 130Pd for low-risk prostate cancer: Preliminary PSA outcomes from a prospective randomized multicenter trial. Int J Radiat Oncol Biol Phys 57 (2003) 1297-1303
33. Nath R., Anderson L.L., Luxton G., et al. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine. Med Phys 22 (1995) 209-234
34. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-The evidence report. National Institutes of Health. Obes Res Suppl. 2 (1998) 51S-209S
35. Thames H., Kuban D., Levy L., et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 57 (2003) 929-943
36. Consensus statement: Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
37. Vicini F.A., Kestin L.L., and Martinez A.A. The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 45 (1999) 553-561
38. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
39. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50 (1966) 163-170
40. Cox D.R. Regression models and life tables. J R Stat Soc Series B 34 (1972) 187-229
41. Loeb S., Yu X., Nadler R.B., et al. Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy?. J Urol 177 (2007) 102-106 discussion, 106
42. Baillargeon J., Pollock B.H., Kristal A.R., et al. The association of body mass index and prostate-specific antigen in a population-based study. Cancer 103 (2005) 1092-1095
43. Roach III M., Hanks G., Thames Jr. H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
44. Kuban D.A., Levy L.B., Potters L., et al. Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 65 (2006) 1487-1493
45. Pasulka P.S., Bistrian B.R., Benotti P.N., et al. The risks of surgery in obese patients. Ann Intern Med 104 (1986) 540-546
46. Song P.Y., Washington M., Vaida F., et al. A comparison of four patient immobilization devices in the treatment of prostate cancer patients with three dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 34 (1996) 213-219
47. Millender L.E., Aubin M., Pouliot J., et al. Daily electronic portal imaging for morbidly obese men undergoing radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 59 (2004) 6-10
48. Rockhill J., Wallner K., Hoffman C., et al. Prostate brachytherapy in obese patients. Brachytherapy 1 (2002) 54-60
49. Merrick G.S., Butler W.M., Wallner K., et al. Permanent prostate brachytherapy-induced morbidity in patients with grade II and III obesity. Urology 60 (2002) 104-108
50. Blasko J.C., Grimm P.D., Sylsvester J.E., et al. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 57 (2000) 273-278
51. Merrick G.S., Butler W.M., Wallner K.E., et al. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 61 (2005) 32-43
52. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 360 (2002) 103-106
53. Pilepich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-Long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 (2005) 1285-1290
54. Denham J.W., Steigler A., Lamb D.S., et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 6 (2005) 841-850
55. D'Amico A.V., Manola J., Loffredo M., et al. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 292 (2004) 821-827
56. Barry M.J., Delorenzo M.A., Walker-Corkery E.S., et al. The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: A population-based cohort study. BJU Int 98 (2006) 973-978
57. Potters L., Torre T., Ashley R., et al. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy. J Clin Oncol 18 (2000) 1187-1192
58. Merrick G.S., Butler W.M., Wallner K.E., et al. Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 65 (2006) 669-677
59. Smith M.R., Finkelstein J.S., McGovern F.J., et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87 (2002) 599-603
60. D'Amico A.V. Predicting prostate-specific antigen recurrence established: Now, who will survive?. J Clin Oncol 20 (2002) 3188-3190